Epidemiology of Klebsiella Pneumoniae in China

NCT ID: NCT03598543

Last Updated: 2018-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-01

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Klebsiella pneumoniae is one of the most common pathogens causing both community-onset and nosocomial infection. More worse, the emergency of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) had cause the clinical therapy be very difficult. However, there is not much empirical data as to the prevalence, risk factors, characteristics,outcomes and the rationality of the current therapy for the Klebsiella pneumoniae infection in China.Thus, the study was aimed to investigate the epidemiology and risk factors, characteristics, outcomes and the rationality of the current therapy for the Klebsiella pneumoniae infection in China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All the patients with culture positive of Klebsiella pneumoniae were screened and reported to the the clinical doctors and confirmed by them. And the clinical characteristics of the patiens, such as baseline data, outcomes etc, were recorded. Finially, to find the prevalence, risk factors, characteristics, outcome and the rationality of the current therapy for the Klebsiella pneumoniae infection in China.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Klebsiella Pneumoniae Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carbapenem-Sensitive K. pneumoniae

Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.

no intervention

Intervention Type OTHER

no intervention, this is an obervational study.

Carbapenem-Resistant K. pneumoniae

Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.

no intervention

Intervention Type OTHER

no intervention, this is an obervational study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

no intervention, this is an obervational study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- new confirmed community-onset or noscomial infection of Klebsiella pneumoniae infection

Exclusion Criteria

* Age\<18, or \>85 years old; Mixed infection of Klebsiella pneumoniae and other microbes
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sir Run Run Shaw Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jian-cang Zhou M.D.

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yun-song Yu, MD

Role: PRINCIPAL_INVESTIGATOR

Zhejiang University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ying-zhi FANG, Master

Role: CONTACT

+86 57186006811

Ping Zhang, MD

Role: CONTACT

+86-571-8600-6142

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ying-zhi Fang

Role: primary

+86 571 86006987

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SRRSH-China-KP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.